天新药业
(603235)
| 流通市值：40.84亿 | | | 总市值：121.57亿 |
| 流通股本：1.47亿 | | | 总股本：4.38亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 618,910,665.47 | 2,208,570,173.44 | 1,613,579,810.79 | 1,066,613,193.86 |
| 营业收入 | 618,910,665.47 | 2,208,570,173.44 | 1,613,579,810.79 | 1,066,613,193.86 |
| 二、营业总成本 | 371,946,946.36 | 1,474,222,808.06 | 1,058,098,256.39 | 671,166,795.68 |
| 营业成本 | 310,504,139.19 | 1,280,721,611.98 | 931,582,176.69 | 618,000,807.55 |
| 税金及附加 | 4,853,558.64 | 22,726,602.49 | 15,942,085.61 | 10,068,656.33 |
| 销售费用 | 8,694,796.65 | 32,849,944.34 | 24,631,752.99 | 17,043,652.05 |
| 管理费用 | 35,356,960.95 | 144,174,525.13 | 98,966,470.13 | 58,414,659.61 |
| 研发费用 | 20,722,319.47 | 103,818,345.37 | 72,715,184.45 | 45,045,430.51 |
| 财务费用 | -8,184,828.54 | -110,068,221.25 | -85,739,413.48 | -77,406,410.37 |
| 其中:利息费用 | - | 3,950,394.8 | - | 2,060,740.77 |
| 其中:利息收入 | 14,257,098.01 | 59,361,872.31 | - | 44,305,423.66 |
| 加:公允价值变动收益 | -2,208,868.2 | 2,238,666.8 | - | - |
| 加:投资收益 | 3,822,583.42 | 5,444,358.6 | 3,650,670.48 | 364,869.03 |
| 资产处置收益 | -407.12 | 962.33 | 962.33 | - |
| 资产减值损失(新) | - | -7,542,795.49 | -5,231,148.92 | -5,231,148.92 |
| 信用减值损失(新) | -780,792.6 | -3,463,779.99 | -1,894,901.85 | -2,643,402.43 |
| 其他收益 | 12,108,734.03 | 43,330,750.67 | 35,733,010.74 | 23,961,148.05 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 259,904,968.64 | 774,355,528.3 | 587,740,147.18 | 411,897,863.91 |
| 加:营业外收入 | 81,612.14 | 1,060,805.27 | 41,460.68 | 31,985.75 |
| 减:营业外支出 | 70,860.72 | 3,643,954.34 | 2,797,593.87 | 1,866,086.93 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 259,915,720.06 | 771,772,379.23 | 584,984,013.99 | 410,063,762.73 |
| 减:所得税费用 | 41,348,618.32 | 120,549,239.62 | 90,501,036.02 | 64,895,301.29 |
| 六、净利润 | 218,567,101.74 | 651,223,139.61 | 494,482,977.97 | 345,168,461.44 |
| 持续经营净利润 | 218,567,101.74 | 651,223,139.61 | 494,482,977.97 | 345,168,461.44 |
| 归属于母公司股东的净利润 | 218,567,101.74 | 651,223,139.61 | 494,482,977.97 | 345,168,461.44 |
| (一)基本每股收益 | 0.5 | 1.49 | 1.13 | 0.79 |
| (二)稀释每股收益 | 0.5 | 1.49 | 1.13 | 0.79 |
| 九、综合收益总额 | 218,567,101.74 | 651,223,139.61 | 494,482,977.97 | 345,168,461.44 |
| 归属于母公司股东的综合收益总额 | 218,567,101.74 | 651,223,139.61 | 494,482,977.97 | 345,168,461.44 |
| 公告日期 | 2025-04-30 | 2025-04-26 | 2024-10-30 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |